
News|Articles|April 3, 2026
Q2 2026 Preview: 6 FDA Decisions to Watch
Author(s)Victoria Johnson
Fact checked by: Tim Smith
Check out 6 FDA decisions to watch in Q2 2026, listed chronologically by expected decision date.
Advertisement
Advertisement
The first quarter of 2026 established a brisk regulatory pace that Q2 shows no signs of slowing. In the span of 3 months, the
Related to this article

Stay updated with the latest healthcare breakthroughs, including 96-week durability data for GSK’s bepirovirsen in hepatitis B, and more.

Despite lowering free IL-6 and hsCRP, monthly ziltivekimab did not reduce 3-point MACE vs placebo in 6376 patients with ASCVD and CKD.

Juanita Mora, MD, of Chicago Allergy Center discusses strategies from boosters and antiviral prophylaxis to specialist counseling.

The FDA approved asundexian with antiplatelet therapy after non-cardioembolic ischemic stroke or high-risk TIA, based on OCEANIC-STROKE data.

Mona Shahriari, MD, and Valerie D. Callender, MD, discuss trial diversity, better outcome measures, and how investigators can earn patient trust.

In a UCB-funded network meta-analysis of 17 trials, bimekizumab ranked first on HiSCR50, HiSCR75, and IHS4-55 among HS drugs at Weeks 12 - 16.

Kausik Ray, MD, MBChB, MPhil, discusses Lp(a)HORIZON, remnant cholesterol targets, enlicitide, and the lipid outcome trials to watch in 2027.
Advertisement
Advertisement

